Please login to the form below

Not currently logged in

Diurnal files adrenal insufficiency drug Alkindi in US

Could become only treatment for children with the condition


UK specialty drugmaker Diurnal has filed its Alkindi Sprinkle replacement therapy for children with adrenal insufficiency in the US, a group with few treatment options.

Diurnal said the US marketing application follows a meeting with the FDA which said it would be able to file Alkindi (hydrocortisone granules) under the regulatory pathway for generic drugs, which hinges on showing bioequivalence to standard hydrocortisone tablets.

There are estimated to be approximately 4,500 children with adrenal insufficiency under the age of 17 in the US, and Diurnal has also indicated it will ask the FDA to confirm the drug’s orphan status in the US “which requires the company to demonstrate significant clinical benefit for the product compared to existing therapies”.

The US filing comes on schedule and is another boost for Diurnal as it recovers from a tricky period after its other lead product Chronocort failed to meet its primary objective in a pivotal congenital adrenal hyperplasia (CAH) study in 2018.

Chronocort is now set for a marketing application in Europe before year-end, according to remarks made at the company’s recent annual general meeting.

Alkindi has already been approved in Europe and launched in its first markets – including Germany and the UK – and is specifically designed to allow easier dosing in paediatric patients compared to conventional hydrocortisone tablets.

The two halves of the Alkindi capsules are twisted apart and the granules within can poured directly onto the child’s tongue, administered using a spoon, or sprinkled on food.

The US marketing application is particularly important for Diurnal as if approved, Alkindi will become the only licensed treatment specifically designed for use in children with adrenal insufficiency, where there is a significant unmet patient need, says chief executive Martin Whitaker.

He is anticipating approval of Alkindi in the US in “late 2020”, and Diurnal has previously indicated it wants to find a US commercial partner for Alkindi and Chronocort in the first half of next year.

Alkindi’s roll-out and sales growth in Europe are progressing “in line with expectations”, according to Diurnal, which reckons the market opportunity for diseases resulting from cortisol deficiency in the US and Europe is over $3bn.

The drug made its debut in Germany in 2018, marking Diurnal’s first-ever product launch, but suffered a setback after the country’s Institute for Quality and Efficiency in Health Care (IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.

It has since been backed by the Scottish Medicines Consortium (SMC) for reimbursement on the NHS.

Article by
Phil Taylor

2nd December 2019

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....